ν μΈλΌλ
ν μΈλΌλμ μμν μ μ©μΌλ‘ κ°λ°λ κ²½κ΅¬μ© νμ μΉλ£μ λ‘, μλΆμ ν°λ‘μ ν€λμ μ΅μ μ (TKI)λ‘ λΆλ₯λ©λλ€. **μ£Όμ μ μμ¦:** * κ΅μ λ¦Όνμ μΉ¨λ² μ¬λΆμ κ΄κ³μμ΄ λ°λ €κ²¬μ 2λ±κΈ λλ 3λ±κΈ μ¬λ°μ± νΌλΆ **λΉλ§μΈν¬μ’ (MCT)** μΉλ£μ λ‘ FDA μΉμΈμ λ°μμ΅λλ€. **μ€νλΌλ²¨ / μ°κ΅¬ μ€μΈ μ©λ:** * μ‘μ’ , μμ’ , νμμ’ λ° λ€λ°μ± 골μμ’ μ ν¬ν¨ν λ°λ €κ²¬μ λ€μν μ’ μ μΉλ£μ μ μ©ν μ μμ΅λλ€. * μ’ μ νκ΄ μ μ λ° μ±μ₯μ μ΅μ νκΈ° μν **λ©νΈλ‘λ Έλ―Ή ννμλ²**(μ μ©λμ νμμ λ₯Ό μ§μμ μΌλ‘ ν¬μ¬νλ μλ²) νλ‘ν μ½μ μΌλΆλ‘ μ μ λ λ§μ΄ νμ©λκ³ μμ΅λλ€.
μμ© κΈ°μ : Toceranib competitively inhibits **ATP** binding at the intracellular kinase domain of several split kinase receptor tyrosine kinases (RTKs). **Key Targets:** * **VEGFR-2** (Vascular Endothelial Growth Factor Receptor-2) * **PDGFR-Ξ²** (Platelet-Derived Growth Factor Receptor-Beta) * **c-Kit** (Stem Cell Growth Factor Receptor) **Pathway:** Inhibition of RTKs β prevents receptor phosphorylation β blocks downstream signal transduction β exerts an antiproliferative effect on endothelial cells and induces cell cycle arrest and apoptosis in tumor cells. Because canine mast cell tumor growth is frequently driven by activating mutations in **c-Kit**, toceranib directly targets the neoplastic cells while simultaneously reducing tumor angiogenesis via **VEGFR-2** and **PDGFR-Ξ²** inhibition.
λλ¬Ό μ’ λ³ μ©λ
- Malignancies (Off-label) Β· 2.5 mg/kg (range 1.5-3.25 mg/kg) Β· PO Β· Monday, Wednesday, Friday basis (or less frequently q48h) Β· Ongoing based on response and toxicity Β· Limited information available. Off-label use.
- Patnaik grade II or III, recurrent, cutaneous mast cell tumors (Label Dose) Β· 3.25 mg/kg PO every other day (q48h) Β· PO Β· q48h Β· Ongoing as tolerated Β· Dose reductions of 0.5 mg/kg (to a minimum dose of 2.2 mg/kg every other day) and dose interruptions for up to two weeks may be utilized to manage adverse reactions. Do not split tablets.
- Patnaik grade II or III, recurrent, cutaneous mast cell tumors (Clinical Experience Dose) Β· 2.5-2.75 mg/kg PO every other day Β· PO Β· q48h Β· Ongoing as tolerated Β· Often better tolerated than the label dose, resulting in less toxicity and fewer drug holidays. Alternatively, a Monday/Wednesday/Friday schedule may be used, especially when combined with other drugs in metronomic protocols.
- Mast cell tumours and other malignancies Β· 2.5-3.25 mg/kg Β· PO Β· q48h or on a Monday, Wednesday, Friday basis Β· Ongoing based on response and toxicity Β· Monitor closely. See Appendix for specific chemotherapy protocols.
μ©λμ λ©΄ν μμ μ λ¬Έκ°λ₯Ό μν μμ μ°Έκ³ μλ£μ λλ€. νμ μ΅μ λΌλ²¨κ³Ό κ°λ³ νμμ λν΄ νμΈνμμμ€.
ν¬μ¬ κ²½λ‘
κΈκΈ°
- Breeding, pregnant, or lactating bitches
- Dogs less than 24 months of age or weighing less than 5 kg (safe use not evaluated)
- Pregnant or lactating bitches
- Dogs < 2 years old
- Dogs < 5 kg
- Patients with any signs of gastrointestinal haemorrhage
- Known hypersensitivity to toceranib
μ΄μλ°μ
- Diarrhea (can be severe)
- Decreased or loss of appetite
- Lameness
- Weight loss
- Gastrointestinal bleeding (blood in stool, melena)
- Muscle cramping
- Neutropenia
- Hypoalbuminemia
- Thromboembolic disease (including pulmonary emboli)
- Vasculitis
- Pancreatitis
- Nasal depigmentation
- Change in coat or skin color
- Epistaxis
- Seizures
- Pruritus
- Diarrhoea
μ½λ¬Ό μνΈμμ©
- NSAIDs (e.g., piroxicam, carprofen) Β· Increased risk of gastrointestinal ulceration or perforation. Use with extreme caution; never give on the same day as toceranib to avoid exacerbating GI toxicity.
- CYP3A4 Inhibitors (e.g., ketoconazole, fluconazole, itraconazole, clarithromycin, verapamil, grapefruit juice) Β· May theoretically increase toceranib plasma concentrations and toxicity. Use with caution.
- Corticosteroids Β· Increased risk of severe gastrointestinal toxicity and ulceration. Β· major
- NSAIDs Β· Increased risk of severe gastrointestinal toxicity and ulceration. Β· major
- Other chemotherapeutic agents Β· Potential for additive myelosuppression and systemic toxicity. Use with caution. Β· moderate
λͺ¨λν°λ§
- CBC (monitor for neutropenia and anemia)
- Hematocrit
- Serum Albumin
- Creatinine
- Serum Phosphate
- Urinalysis
- Full chemistry panels
- Clinical signs of GI toxicity (diarrhea, fresh blood in stool, melena)
- Tumor size and response to therapy
- Blood pressure (baseline and monthly)
- Urinalysis (baseline and monthly, monitor for proteinuria)
- Haematology (baseline and monthly)
- Biochemistry (baseline and monthly, monitor albumin and ALT)
- Coagulation profiles (if adverse signs occur)
- Faecal occult blood tests (if adverse signs occur)
- Weekly owner check-ins for the first 6 weeks to monitor for GI signs
κ³Όμ©λ
Toceranib has a **narrow margin of safety**. While specific acute toxicity data is limited, overdoses are likely to cause severe gastrointestinal distress, myelosuppression, and vascular events. > **Action:** In the event of an acute overdose, consider immediate gut decontamination (emesis/activated charcoal) if caught early. Contact an animal poison control center for further guidance and provide aggressive supportive care.
VetSheet μ½λ¬Ό λ νΌλ°μ€λ λ©΄ν μμ μ λ¬Έκ°λ₯Ό μν μμ μμ¬κ²°μ 보쑰 λꡬμ΄λ©°, μ λ¬Έμ νλ¨μ΄λ μ μ‘°μ¬μ μ΅μ λΌλ²¨μ λμ νμ§ μμ΅λλ€.